期刊：
BMC Complementary Medicine and Therapies,2024年24(1):1-12 ISSN：2662-7671
通讯作者：
Liqing Li<&wdkj&>Bin Liu<&wdkj&>Xiong Cai
作者机构：
[Zhaoli Su; Junping Zhu; Ye Lin; Yuanyuan Tang; Jiaming Wei] Department of Rheumatology, First Hospital, School of Chinese Medical Sciences, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, China;[Yuanyuan Tang] College of Biology, Hunan University, Changsha, Hunan, 410082, China;[Zhaoli Su] The Central Research Laboratory, Hunan Traditional Chinese Medical College, Zhuzhou, China;[Zhaoli Su] Guangxi Provincial Key Laboratory of Preventive and Therapeutic Research in Prevalent Diseases in West Guangxi, Youjiang Medical University for Nationalities, Baise, Guangxi, 533000, China;[Liqing Li] The Central Research Laboratory, Hunan Traditional Chinese Medical College, Zhuzhou, China. liliqing87@qq.com
通讯机构：
[Liqing Li] T;[Bin Liu] C;[Xiong Cai] D;The Central Research Laboratory, Hunan Traditional Chinese Medical College, Zhuzhou, China<&wdkj&>Guangxi Provincial Key Laboratory of Preventive and Therapeutic Research in Prevalent Diseases in West Guangxi, Youjiang Medical University for Nationalities, Baise, China<&wdkj&>College of Biology, Hunan University, Changsha, China<&wdkj&>Department of Rheumatology, First Hospital, School of Chinese Medical Sciences, Hunan University of Chinese Medicine, Changsha, China
摘要：
BACKGROUND: Rheumatoid arthritis (RA) is a prevalent autoimmune disease marked by chronic synovitis as well as cartilage and bone destruction. Halofuginone hydrobromide (HF), a bioactive compound derived from the Chinese herbal plant Dichroa febrifuga Lour., has demonstrated substantial anti-arthritic effects in RA. Nevertheless, the molecular mechanisms responsible for the anti-RA effects of HF remain unclear. METHODS: This study employed a combination of network pharmacology, molecular docking, and experimental validation to investigate potential targets of HF in RA. RESULTS: Network pharmacology analyses identified 109 differentially expressed genes (DEGs) resulting from HF treatment in RA. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses unveiled a robust association between these DEGs and the IL-17 signaling pathway. Subsequently, a protein-protein interaction (PPI) network analysis revealed 10 core DEGs, that is, EGFR, MMP9, TLR4, ESR1, MMP2, PPARG, MAPK1, JAK2, STAT1, and MAPK8. Among them, MMP9 displayed the greatest binding energy for HF. In an in vitro assay, HF significantly inhibited the activity of inflammatory macrophages, and regulated the IL-17 signaling pathway by decreasing the levels of IL-17C, p-NF-κB, and MMP9. CONCLUSION: In summary, these findings suggest that HF has the potential to inhibit the activation of inflammatory macrophages through its regulation of the IL-17 signaling pathway, underscoring its potential in the suppression of immune-mediated inflammation in RA.
作者机构：
[He, Xuan; Tang, Siqin; Guo, Bing] The Second Affiliated Hospital of Hunan University of Chinese Medicine, Changsha 410005, China;[Yu, Yunfeng; Liu, Qili; Wang, Min] The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha 410007, China;[Li, Ronghui] College of Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, China;[Mao, Yilin] The Second Affiliated Hospital of Hunan University of Chinese Medicine, Changsha 410005, China. Electronic address: maoyilin8518@126.com
摘要：
The aim of this article is to introduce the roles and mechanisms of the JAK2/STAT3 pathway in various cardiovascular diseases, such as myocardial fibrosis, cardiac hypertrophy, atherosclerosis, myocardial infarction, and myocardial ischemiareperfusion. In addition, the effects of phytochemical ingredients and different natural plants, mainly traditional Chinese medicines, on the regulation of different cardiovascular diseases via the JAK2/STAT3 pathway are discussed. Surprisingly, the JAK2 pathway has dual roles in different cardiovascular diseases. Future research should focus on the dual regulatory effects of different phytochemical ingredients and natural plants on JAK2 to pave the way for their use in clinical trials.
作者机构：
[Liuting Zeng] Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Graduate School of Peking Union Medical College, Nanjing, China. zltab2016@hotmail.com;[Kailin Yang] Hunan University of Chinese Medicine, Changsha, China;[Qi He] People's Hospital of Ningxiang City, Ningxiang, China;[Xiaofei Zhu] Fudan University, Shanghai, China;[Zhiyong Long] Department of Rehabilitation Medicine, Guangzhou Panyu Central Hospital, Guangzhou, China
通讯机构：
[Liuting Zeng; Lingyun Sun] D;Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Graduate School of Peking Union Medical College, Nanjing, China<&wdkj&>Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Graduate School of Peking Union Medical College, Nanjing, China<&wdkj&>Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
摘要：
Previous randomized controlled trials (RCTs) suggested that gut microbiota-based therapies may be effective in treating autoimmune diseases, but a systematic summary is lacking. Pubmed, EMbase, Sinomed, and other databases were searched for RCTs related to the treatment of autoimmune diseases with probiotics from inception to June 2022. RevMan 5.4 software was used for meta-analysis after 2 investigators independently screened literature, extracted data, and assessed the risk of bias of included studies. A total of 80 RCTs and 14 types of autoimmune disease [celiac sprue, SLE, and lupus nephritis (LN), RA, juvenile idiopathic arthritis (JIA), spondyloarthritis, psoriasis, fibromyalgia syndrome, MS, systemic sclerosis, type 1 diabetes mellitus (T1DM), oral lichen planus (OLP), Crohn’s disease, ulcerative colitis] were included. The results showed that gut microbiota-based therapies may improve the symptoms and/or inflammatory factor of celiac sprue, SLE and LN, JIA, psoriasis, PSS, MS, systemic sclerosis, Crohn’s disease, and ulcerative colitis. However, gut microbiota-based therapies may not improve the symptoms and/or inflammatory factor of spondyloarthritis and RA. Gut microbiota-based therapies may relieve the pain of fibromyalgia syndrome, but the effect on fibromyalgia impact questionnaire score is not significant. Gut microbiota-based therapies may improve HbA1c in T1DM, but its effect on total insulin requirement does not seem to be significant. These RCTs showed that probiotics did not increase the incidence of adverse events. Gut microbiota-based therapies may improve several autoimmune diseases (celiac sprue, SLE and LN, JIA, psoriasis, fibromyalgia syndrome, PSS, MS, T1DM, Crohn’s disease, and ulcerative colitis).
